Analysts at Leerink Partnrs raised their FY2026 EPS estimates for shares of Travere Therapeutics in a research note issued to investors on Tuesday, February 11th. Leerink Partnrs analyst J. Schwartz ...
Phathom Pharmaceuticals (NASDAQ:PHAT) traded higher on Friday after Cantor Fitzgerald initiated its coverage with an overweight recommendation despite a recent selloff attributed to the company's IP ...
Highlights,Cantor Fitzgerald raised DoorDash’s price projection from $200 to $230.,Several financial firms, including ...
Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback